Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2024-09-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
第六届董事会第十次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the company's sixth board of directors' tenth (extraordinary) meeting. It details the meeting's convening, attendance, and the approval of several proposals including stock incentive grants, related party transactions, and investment fund participation. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions and approvals. It is a typical board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is 2328 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report.
2024-09-23 Chinese
监事会关于2023年限制性股票激励计划预留授予激励对象名单（截至预留授予日）的核查意见
Regulatory Filings Classification · 95% confidence The document is an official announcement from the supervisory board of Yingkang Life Technology Co., Ltd. regarding the verification opinion on the reserved grant list of incentive objects under the 2023 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, eligibility of incentive recipients, and approval of the reserved grant date and stock grant details. The document is short (1208 characters) and serves as a formal announcement of the incentive plan details rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion. This type of announcement fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure about stock incentive plans without being a full report or a proxy solicitation.
2024-09-23 Chinese
盈康生命：2023年限制性股票激励计划预留授予激励对象名单（截至预留授予日）
Share Issue/Capital Change Classification · 95% confidence The document is titled '2023 年限制性股票激励计划 预留授予激励对象名单（截至预留授予日）' which translates to '2023 Restricted Stock Incentive Plan Reserved Grant Incentive Object List (as of the reserved grant date)'. It lists the allocation of restricted stock to core employees and provides details on the number of shares granted and the proportion of total shares. The document is focused on stock incentive plans and the distribution of restricted shares to employees. It does not contain financial statements, earnings data, or regulatory certifications. It is not an announcement of a report but a detailed disclosure of share-based incentive allocations. This fits best under the category of Share Issue/Capital Change (SHA), as it relates to the issuance and allocation of restricted stock under an incentive plan.
2024-09-23 Chinese
第六届监事会第九次（临时）会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 盈康生命科技股份有限公司 regarding decisions made in their ninth (extraordinary) meeting. It includes details about the meeting's attendance, voting results, and approvals of specific corporate matters such as stock incentive plans and related party transactions. The document does not contain financial statements or detailed financial data but rather reports on governance decisions and approvals. It also references other announcements published separately on the information disclosure website. The document length is short (2133 characters) and is clearly a meeting resolution announcement rather than a full report or financial filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-09-23 Chinese
关于公司与专业投资机构共同投资的进展暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of a company's joint investment with professional investment institutions and related party transactions. It includes extensive information about the investment fund, the involved parties, their financial data, the investment agreement, and governance of the fund. The document is not a financial report like an annual or interim report, nor is it a transcript, audit report, or earnings release. It is a regulatory announcement about a capital investment and related party transaction, describing the structure, approval, and risks of the investment. The document is lengthy (15,000 characters) and contains substantive details about the investment and related transactions, which aligns with a Capital/Financing Update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-09-23 Chinese
盈康生命科技股份有限公司2022年度向特定对象发行股票募集说明书（注册稿）（2024年半年报数据更新稿）
Capital/Financing Update Classification · 95% confidence The document is titled "2022 年度向特定对象发行股票募集说明书（注册稿）" which translates to "2022 Annual Private Placement Stock Issuance Prospectus (Registration Draft)". It is a detailed prospectus related to a specific stock issuance to particular investors, including extensive information about the company, risk factors, issuance details, pricing, shareholder approvals, regulatory approvals, and use of proceeds. The document includes financial data, risk disclosures, legal and regulatory compliance statements, and detailed sections on the issuance plan and related corporate governance matters. This type of document is a capital raising disclosure related to a private placement or specific share issuance, which fits the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or proxy statement, but a detailed fundraising document. The length and detail confirm it is the actual document, not just an announcement or summary. Therefore, the correct classification is CAP with high confidence.
2024-08-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.